, an emerging inhaled drug delivery company based in
Research Triangle Park, announced today that it has been granted a
United States Patent (6,889,690; issue date May 10th) for multi-dose
dry powder drug packages for holding pharmaceutical grade formulations
of inhalable dry powder substances . is an
emerging inhaled drug delivery company based on innovative technology
for aerosolizing powders using the application of powder-specific
electrical frequencies.

cartoning subassembly

Atkins, Ph. This
patent is the first of a series of patents that we expect to obtain to
protect our multi-dose inhaled dry powder products, the first of which
will be a compound for the treatment of asthma and COPD. Working with
early stage and virtual companies has allowed us to follow those companies'
product into the commercial fill/finish market.0 million and will consist of three new manufacturing suites.

blending pouches

Oriel 's proprietary dry powder inhalation technology will impact
the way in which some illnesses such as asthma, chronic obstructive
pulmonary disease (COPD) and cystic fibrosis can be treated and may
also be applied to the delivery of both medications that require
efficient lung delivery and those drugs that are currently
administered via injection., MicroTest Laboratories Inc.

Manufacturing facilities that package goods for private label companies or for their own product with services for pricate label companies.

pouches cleanroom

The vibration is individually tailored for a
given drug product through use of powder physics principles and
provides highly efficient dose delivery.com

AGAWAM, Mass.,
(MTL) announces that it will be manufacturing two commercial pharmaceutical
products in 2006.

MTL is a privately held contract laboratory (CRO) and a contract
manufacturer (CMO) with the majority of activities in the life science
industry.

filling fulfillment

The patent covers aspects of Oriel's multi -dose dry powder inhaler
technology that provides a package to apply vibration directly to a
powder drug as well as a design for delivery of drugs. Utilizing technology developed at the
University of North Carolina at Chapel Hill, Oriel is committed to
developing dry powder inhaler (DPI) products with their own energy
source for drug delivery to the lungs and thereby better treat
respiratory and pulmonary diseases.

kds blister

"
Oriel Therapeutics Inc. These products will further expand MTL's growing portfolio
of contract manufacturing activities.

refurbish kds

in separate blisters). Oriel's design enables
increased formulation flexibility in the development of combination
products.orieltherapeutics . Richter also indicated
that the aggressive 2007 strategy forecasts sales revenues nearly double those
of 2005.

blister pouches

" Our core
technology and ability to maintain our skilled workforce have been
instrumental in our continued success and growth.

epd cleanroom

MTL's entry into contract manufacturing
began with clinical scale fill/finish of pharmaceuticals and biotechnology
products such as vaccines and cancer therapeutics ." MTL will expand again this
year with another considerably sized build out.

fulfillment cleanroom

Commenting for Oriel Therapeutics, Inc. Dr.

sps shrink

The new $5. The biotechnology and pharmaceutical services include
formulation , aseptic filling and stability testing.

epd blending

The package can
be configured to deliver drugs in combination without blending (i.

For more information visit www. Dr.

sheeting cleanroom

S. This final build-out will allow us to
manufacture large scale bio-technology and pharmaceutical products such as the
recombinant botulinum vaccine manufactured in Agawam during 2003. MTL also has a business unit that focuses on cleanroom
testing and validation for both the hospital pharmacy and the life science
industries .

baggs sleeving

Oriel Therapeutics Inc. Awarded Its First U.S. Patent

bagging refurbish

C.
Combination therapies are increasingly being used in the treatment
of asthma today., CEO Paul J.
Richter said these suites will be the foundation of our business strategy for
many years to come.

bagging submited

pouches wrapping

MicroTest Laboratories Announces Commercial Manufacturing Project

Dr. This expansion will cost
roughly $2.

sleeving kds

epd filling

D. Steven Richter,
President and CEO stated today, "We have been manufacturing phase I/II
products for the last three years.

Example: Company that packages the end product which is going to a market or store.

epd kds

----Oriel
Therapeutics Inc.

About Oriel Therapeutics

Based in Research Triangle Park, Oriel Therapeutics Inc . "Our plans for 2007 are aggressive and will require an
additional 7 million in financing.

fulfillment thermoforming

e. Since 2003, we have created
approximately 25 life science jobs as a result of the expansion.

wrapping kds

The current markets for topical and systemic
pulmonary delivery are significant, approximately $10 billion, and are
projected to grow to in excess of $20 billion by the end of the decade
due to an increasing prevalence of asthma and COPD along with expected
approvals for inhaled insulin therapy. In addition to contract manufacturing, MTL tests medical devices,
biologics and pharmaceuticals for contamination related to manufacturing of
these products.

cleanroom subassembly

This coupled with the powder delivery technology will allow
for more rapid product development and improved patient
administration.3 million expansion was
completed in August 2005, and will allow us to expand into contract
manufacturing of commercial scale products.

Manufacturing facilities that make supplies or components for packaging should be submited to Manufacturing/Packaging.

fas kds

Business Editors/Health Editors

RESEARCH TRIANGLE PARK, N.
said, "We are very pleased to be granted our first US patent.

submited sheeting

, currently has 11 U. and associated
international patent applications pending for a variety of aspects of
its technology.